MoonLake CSO-linked entity sells 52,448 shares

MoonLake Immunotherapeutics reported that JeruCON Beratungsgesellschaft mbH, an entity associated with Chief Scientific Officer Kristian Reich, sold 50,000 and 2,448 Class A ordinary shares on July 21–22, 2026.

Rhea-AI Filing Summary

MoonLake Immunotherapeutics reported that JeruCON Beratungsgesellschaft mbH, an entity associated with Chief Scientific Officer Kristian Reich, sold 50,000 and 2,448 Class A ordinary shares on July 21–22, 2026. The 50,000-share block was sold at a weighted average price of $20.0200 per share, in trades between $20.00 and $20.06, and the 2,448-share block at $20.00 per share. Both sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 10, 2026.

Reich may be deemed the indirect beneficial owner of JeruCON’s shares and directly held 35,389 Class A ordinary shares as of July 21, 2026.

Insider Trade Summary 10b5-1

Net Seller: 52,448 shares

Net Sell 3 txns

Insider Reich Kristian

Role Chief Scientific Officer

Sold 52,448 shs ($1.05M)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share F1, F3	2,448	$20.00	$49K
Sale	Class A ordinary shares, par value $0.0001 per share F1, F2, F3	50,000	$20.02	$1.00M
holding	Class A ordinary shares, par value $0.0001 per share	--	--	--

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 2,712,298 shares (Indirect, See footnote.); Class A ordinary shares, par value $0.0001 per share — 35,389 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

Key Figures

Total shares sold: 52,448 shares First sale size: 50,000 shares Second sale size: 2,448 shares +3 more

6 metrics

Total shares sold 52,448 shares Non-derivative sales reported for July 21–22, 2026

First sale size 50,000 shares Non-derivative sale on 2026-07-21 by JeruCON Beratungsgesellschaft mbH

Second sale size 2,448 shares Non-derivative sale on 2026-07-22 by JeruCON Beratungsgesellschaft mbH

Weighted average price $20.0200 per share 50,000-share sale on 2026-07-21; trades between $20.00 and $20.06

Price per share $20.00 per share 2,448-share sale on 2026-07-22

Direct holdings after transaction 35,389 shares Class A ordinary shares held directly by Kristian Reich as of 2026-07-21

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, indirect beneficial owner

3 terms

Rule 10b5-1 trading plan financial

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

indirect beneficial owner financial

"may be deemed for purposes of Section 16 ... to be the indirect beneficial owner of the ordinary shares"

FAQ

What insider share sales did MoonLake Immunotherapeutics (MLTX) report in this Form 4?

MoonLake Immunotherapeutics reported two insider-related sales totaling 52,448 Class A shares. An entity linked to Chief Scientific Officer Kristian Reich sold 50,000 shares and 2,448 shares on July 21–22, 2026, at prices around $20 per share.

Who executed the MLTX share sales and what is Kristian Reich’s role?

The reported sales involve shares owned by JeruCON Beratungsgesellschaft mbH, with Kristian Reich as MoonLake’s Chief Scientific Officer. Reich may be deemed an indirect beneficial owner of JeruCON’s holdings under Section 16 of the Exchange Act.

Were the MoonLake Immunotherapeutics (MLTX) insider sales made under a Rule 10b5-1 plan?

Yes. Both reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. Rule 10b5-1 plans pre-arrange trading instructions, which can lessen the informational value of the specific trade timing.

At what prices were the MLTX shares sold in these insider transactions?

The 2,448-share sale on July 22, 2026 occurred at $20.00 per share. The 50,000-share sale on July 21, 2026 had a weighted average price of $20.0200, with individual trades executed between $20.00 and $20.06 per share.

How many MoonLake Immunotherapeutics (MLTX) shares does Kristian Reich still hold directly?

After the reported activity, Kristian Reich directly held 35,389 Class A ordinary shares as of July 21, 2026. This direct position is separate from his indirect beneficial interest in shares owned by JeruCON Beratungsgesellschaft mbH.

Are the MLTX shares sold held directly by Kristian Reich or through another entity?

The sold shares are owned by JeruCON Beratungsgesellschaft mbH. Reich may be deemed an indirect beneficial owner of these ordinary shares but they are reported as indirectly held, reflecting ownership through that associated entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:05 PM Accepted by SEC EDGAR 07/23/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reich Kristian

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	07/21/2026		S(1)		50,000	D	$20.02(2)	2,714,746	I	See footnote.(3)
Class A ordinary shares, par value $0.0001 per share	07/22/2026		S(1)		2,448	D	$20	2,712,298	I	See footnote.(3)
Class A ordinary shares, par value $0.0001 per share								35,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)